Brokerages Set Evolus, Inc. (NASDAQ:EOLS) PT at $20.80

Shares of Evolus, Inc. (NASDAQ:EOLS) have been assigned an average rating of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $20.1667.

A number of research analysts recently issued reports on EOLS shares. Wall Street Zen raised shares of Evolus from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Evolus in a research note on Monday, December 22nd. Stifel Nicolaus lowered their price target on Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a report on Tuesday. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Evolus in a research report on Friday, January 9th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Evolus in a research report on Wednesday, December 24th.

Insider Activity

In other Evolus news, insider David Moatazedi sold 10,539 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $7.15, for a total value of $75,353.85. Following the sale, the insider owned 354,388 shares in the company, valued at $2,533,874.20. This trade represents a 2.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 5.90% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Manchester Capital Management LLC acquired a new position in Evolus in the 2nd quarter valued at approximately $26,000. State of Alaska Department of Revenue acquired a new stake in shares of Evolus in the 3rd quarter valued at about $26,000. Wexford Capital LP bought a new position in Evolus in the third quarter worth approximately $37,000. Aquatic Capital Management LLC bought a new stake in shares of Evolus during the third quarter valued at approximately $48,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Evolus during the third quarter worth approximately $62,000. Institutional investors own 90.69% of the company’s stock.

Evolus Trading Up 4.0%

Shares of EOLS stock opened at $5.20 on Friday. The stock has a market cap of $337.06 million, a P/E ratio of -5.65 and a beta of 0.91. Evolus has a 1 year low of $4.74 and a 1 year high of $17.12. The stock has a 50 day simple moving average of $6.67 and a 200 day simple moving average of $7.16.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The firm had revenue of $68.97 million for the quarter, compared to analyst estimates of $91.23 million. Analysts forecast that Evolus will post -0.61 EPS for the current year.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.